#FierceBiotech
FierceBiotech: How NIH’s Nicole Kleinstreuer is working to reduce animal testing while avoiding a ‘backlash’

by Marissa Russo @marissarusso.bsky.social

bit.ly/4dn55Ot
October 6, 2026 at 5:33 PM
📰 News Snapshot (24h) · 🔴 Dw: US sanctions halt TOEFL and GRE tests in Iran, disrupting study plans · 🟢 Fiercebiotech: Teva autoimmune antibody notches ph. 2 win in celiac disease · 🔴 Investing: Why is United Microelectronics stock sliding today?… #investing #stocks #StockMarket
September 2, 2026 at 3:11 PM
“Boston Scientific halts sales of angiographic catheters amid ‘two serious injuries’” — fiercebiotech

#BostonNews #Boston #BostonMA
September 1, 2026 at 12:49 PM
FierceBiotech : NIH grants powered $94B in economic activity in 2024 and supported more than 400K jobs: report

www.fiercebiotech.com/research/nih...
NIH grants powered $94B in economic activity in 2024 and supported more than 400K jobs: report
Funding granted to researchers by the National Institutes of Health (NIH) powered $94.58 billion in economic activity across the U.S. | Funding granted to researchers by the National Institutes of Hea...
www.fiercebiotech.com
March 12, 2025 at 5:06 AM
JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO via FierceBiotech www.fiercebiotech.com/biotech/jpm2...
JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO
Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. Yesterday saw some high-value dealma...
www.fiercebiotech.com
January 14, 2025 at 6:23 PM
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more via FierceBiotech www.fiercebiotech.com/biotech/jpm2...
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
The J.P. | It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the year.
www.fiercebiotech.com
January 13, 2025 at 8:34 PM
Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts via FierceBiotech www.fiercebiotech.com/biotech/sana...
Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts
Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. | Sana B...
www.fiercebiotech.com
January 10, 2025 at 1:20 AM
Pfizer turns to GPCR experts at Heptares for a lineup of new drugs - FierceBiotech:
February 4, 2026 at 1:05 PM
Johns Hopkins team finds a new drug target for diabetes - FierceBiotech Research:
February 4, 2026 at 12:47 PM
CRISPR-Cas9 pioneer starts recruiting R&D group in Cambridge hub - FierceBiotech:
February 4, 2026 at 12:41 PM
Merck dumps 120 Cubist researchers after its $9.5B merger - FierceBiotech:
February 4, 2026 at 12:40 PM
Raptor jumps as its Huntington's hopeful slows the loss of muscle control - FierceBiotech:
February 4, 2026 at 11:56 AM
Merck's Kim resigns to teach at Stanford med school - FierceBiotech:
February 4, 2026 at 11:48 AM
Global biopharma hub strategy doomed Novartis' outlying R&D facility - FierceBiotech:
February 4, 2026 at 11:43 AM